Summit Therapeutics (SUMM)

 

SUMM Share PerformanceMore

52 week high262.00 04/10/16
52 week low88.00 07/04/16
52 week change 106.50 (110.94%)
4 week volume1,118,250 28/02/17

Media for (SUMM)

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Summit Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference

Summit Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference Summit Therapeutics plc ("Summit", the "Company", or the "Group") SUMMIT THERAPEUTICS TO PRESENT AT THE OPPENHEIMER 27 TH ANNUAL HEALTHCARE CONFERENCE Oxford, UK, 15 March 2017- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SU...

Trends and Targets for 6/03/2017

FTSE FOR THE WEEK (FTSE:UKX) Friday was irritating. It's one thing to speculate "all the action will happen at the open...

Summit Therapeutics Recognises Tenth Annual Rare Disease Day

Summit Therapeutics Recognises Tenth Annual Rare Disease Day Summit Therapeutics plc ('Summit' or 'the Company') SUMMIT THERAPEUTICS RECOGNISES 10 TH ANNUAL RARE DISEASE DAY Oxford, UK, 28 February 2017 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies f...

Summit Therapeutics plc : Exercise of Warrants

Summit Therapeutics plc: Exercise of Warrants Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF WARRANTS Oxford, UK, 23 February 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announce...

Summit to take part in investor conferences

Summit Therapeutics has announced that company management will participate in three upcoming investor conferences ...

Summit Therapeutics to Participate in February Investor Conferences

Summit Therapeutics to Participate in February Investor Conferences Summit Therapeutics plc ("Summit", the "Company", or the "Group") SUMMIT THERAPEUTICS TO PARTICIPATE IN FEBRUARY INVESTOR CONFERENCES Oxford, UK, 2 February 2017- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development c...

Summit outlines Phase 3 programme for ridinilazole

Summit Therapeutics has outlined its Phase 3 programme for its novel antibiotic, ridinilazole, following recent regulatory ...

Summit Outline Phase 3 Programme for Novel CDI Antibiotic Ridinilazole

Summit Outline Phase 3 Programme for Novel CDI Antibiotic Ridinilazole Summit Therapeutics plc ('Summit', the 'Company' or the 'Group') SUMMIT OUTLINES PHASE 3 PROGRAMME FOR NOVEL CDI ANTIBIOTIC RIDINILAZOLE FOLLOWING FDA AND EMA REGULATORY MEETINGS Oxford, UK, 1 February 2017 - Summit Therapeutics plc (AIM...

Fundamental DataMore

EPS-41
Dividend yield0 %

Latest discussion posts More

  • NEW ARTICLE: Trends and Targets for 6/03/2017

    " FTSE FOR THE WEEK (FTSE:UKX)A Friday was irritating. It's one thing to speculate "all the action will happen at the open", quite another to glance at the FTSE at 8:01am ...
    5-Mar-2017
    II Editor
  • RNS Ridinilazole CDI

    Good RNS today to push sp up around 13% to #1.90. The FDA and EMA have agreed with Summit the parameters for the Phase 3 trials. Essentially the authorities want the Phase 3 ...
    1-Feb-2017
    bobsson
  • That`s better

    Great to see sp recovering from the 140s pre new year. Expect to see C dif deal before end of H1. Progress on DMD scientific or anecdotal could come at any time by end of H1. ...
    24-Jan-2017
    bobsson

Users' HoldingsMore

Users who hold Summit Therapeutics also hold..
LLOYDS GRP.22%
RANGE RES.18%
ROYAL BANK SCOT15%
SIRIUS MINERALS15%
ROCKHOPPER12%

Codes & Symbols

ISINGB00BN40HZ01
SymbolsSUMM, LSE:SUMM, SUMM.L, SUMM:LN, LON:SUMM, XLON:SUMM